Close

TS-NKG2DL Anti-hCD3 and Anti-CD4 (Ibalizumab) 28BBζ CAR (XS-0722-YF505)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-Human CD4 chimeric antigen receptor (CAR) is constructed for the engineering of T cells. The receptor construction is 7H-YB-NKG2DL Anti-hCD3 and (OKT3 scFv-NKG2D ECD)-EF1a-scFv-CD28-41BB-CD3ζ. 7H-YB means seven repeats of the HSE motif 5'-nGAAnnTTCnnGAAn-3' upstream of the human synthetic core promoter (YB). 7H-YB is a technology for photothermal control of T cell therapies.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • CD4
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Breast cancer
  • Generation
  • 3nd-generation CAR
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Receptor Construction
  • 7H-YB-NKG2DL Anti-hCD3 and (OKT3 scFv-NKG2D ECD)-EF1a-scFv-CD28-41BB-CD3ζ

Target

  • Clone
  • Ibalizumab
  • Host
  • Mouse
  • Target Species
  • Human
  • Gene Name
  • CD40
  • Synonyms
  • CD40; p50; Bp50; CDW40; TNFRSF5
  • Introduction
  • This gene encodes the CD4 membrane glycoprotein of T lymphocytes. The CD4 antigen acts as a coreceptor with the T-cell receptor on the T lymphocyte to recognize antigens displayed by an antigen presenting cell in the context of class II MHC molecules. The CD4 antigen is also a primary receptor for entry of the human immunodeficiency virus through interactions with the HIV Env gp120 subunit. This gene is expressed not only in T lymphocytes, but also in B cells, macrophages, granulocytes, as well as in various regions of the brain. The protein functions to initiate or augment the early phase of T-cell activation, and may function as an important mediator of indirect neuronal damage in infectious and immune-mediated diseases of the central nervous system. Multiple alternatively spliced transcript variants encoding different isoforms have been identified in this gene.

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System

Customer Reviews and Q&As

There are currently no customer reviews or questions for TS-NKG2DL Anti-hCD3 and Anti-Human CD4 scFv (Ibalizumab) CD28-4-1BB-CD3ζ CAR, pCDCAR1 (XS-0722-YF505). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.